DexCom, Inc. (NASDAQ:DXCM) Position Increased by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 53.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,459 shares of the medical device company’s stock after buying an additional 6,425 shares during the period. Harvest Fund Management Co. Ltd’s holdings in DexCom were worth $1,237,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Taylor Frigon Capital Management LLC increased its holdings in shares of DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the period. Brooktree Capital Management acquired a new position in shares of DexCom in the 3rd quarter valued at about $683,000. National Pension Service increased its holdings in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Intact Investment Management Inc. acquired a new position in shares of DexCom in the 3rd quarter valued at about $650,000. Finally, Waters Parkerson & CO. LLC increased its holdings in shares of DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after purchasing an additional 10,892 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on DXCM shares. Wells Fargo & Company upped their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Barclays dropped their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Sanford C. Bernstein increased their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Finally, Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by company insiders.

DexCom Stock Up 6.9 %

DXCM opened at $77.83 on Tuesday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $30.40 billion, a price-to-earnings ratio of 46.60, a P/E/G ratio of 2.23 and a beta of 1.17. The business has a 50 day moving average of $70.76 and a 200-day moving average of $88.93.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.